The Role of Cardio-Protective Agents in Cardio-Preservation in Breast Cancer Patients Receiving Anthracyclines ± Trastuzumab: A Meta-Analysis of Clinical Studies

Data from a systematic review and meta-analysis of patients with breast cancer receiving ACE inhibitor/ARB/beta-blocker treatment immediately after completing anthracycline with or without trastuzumab demonstrated a significantly lower difference in the mean change of left ventricular ejection fraction, compared to patients who did not receive the cardio-protective agents (standardized mean difference, -2.36; 95% CI: -3.23 to -1.49; p < .00001).

Critical Reviews in Oncology/Hematology